Other Finding — Post-Therapy Skin and Trabecular Thickening
Trabecular thickening with associated skin thickening following surgery and/or radiation therapy. Classified as a typically benign other finding in the BI-RADS v2025 MRI lexicon.
Definition
- Trabecular thickening: thickening of the fibrous septa (Cooper ligaments) that span between the skin and the pectoralis fascia, visible as prominent low-signal strands on T1-weighted images and high-signal strands on fluid-sensitive sequences
- Skin thickening: skin thickness > 2 mm (see Associated Feature — Skin Thickening for general definition)
- The combination is expected after breast-conserving surgery (lumpectomy) with adjuvant radiation therapy and represents post-treatment edema and fibrosis
Imaging Appearance
T2-Weighted / STIR
- Diffuse or regional high signal in the subcutaneous fat and along thickened trabeculae reflecting interstitial edema
- Skin appears thickened with increased T2 signal
- Edema may extend into the chest wall and pectoralis muscle in the early post-radiation period
T1-Weighted (Pre-contrast)
- Thickened trabeculae appear as prominent low-signal linear strands within the subcutaneous fat
- Skin thickening manifests as a widened low-signal band at the breast surface
- Reticular pattern of fluid in subcutaneous tissue may reduce fat signal
Post-contrast T1-Weighted (Fat-suppressed)
- Skin and trabeculae may show mild diffuse enhancement in the acute/subacute post-radiation setting (typically first 6–18 months)
- Enhancement should be non-focal and non-mass-like — any focal enhancing lesion within the treatment bed warrants further evaluation
- Enhancement gradually diminishes over time as fibrosis matures
DWI
- Post-therapy edema may cause mildly elevated signal on DWI and mildly reduced ADC, but not to the degree seen with malignancy
- Should not show focal restricted diffusion
Temporal Evolution
| Time Post-Radiation | Expected Findings |
|---|---|
| 0–6 months | Marked edema, skin thickening, diffuse enhancement, seroma common |
| 6–18 months | Gradually decreasing edema and enhancement, trabecular thickening persists |
| 18–36 months | Edema largely resolved, residual trabecular and skin thickening, minimal enhancement |
| > 3 years | Stable fibrotic changes, skin thickening may persist indefinitely, no significant enhancement |
Board Pearl
Post-radiation changes are most pronounced in the first 6–18 months and should progressively decrease. New or increasing skin/trabecular thickening after an initial period of improvement is a red flag for recurrence or inflammatory carcinoma and warrants biopsy.
Differential Diagnosis
| Entity | Key Distinguishing Features |
|---|---|
| Post-therapy changes (this page) | History of surgery/radiation; diffuse, non-focal; stable or decreasing over time |
| Inflammatory breast cancer | Rapid onset; skin thickening with skin enhancement; often with underlying mass or NME; no prior treatment history |
| Infection / abscess | Focal skin thickening; clinical signs (erythema, warmth, pain); rim-enhancing collection |
| Systemic edema (CHF, renal failure) | Bilateral and symmetric; no treatment history; clinical context |
| Radiation recall | Occurs after chemotherapy in a previously irradiated field; acute onset with erythema |
| Lymphatic obstruction | Axillary adenopathy or prior axillary dissection; ipsilateral; may be progressive |
Board Pearl
The critical distinction is skin thickening vs skin involvement: post-therapy skin thickening is morphologic only (no definitive skin enhancement), while skin involvement requires definitive skin enhancement and raises concern for malignancy (T4b/T4d). Always check post-contrast images.
Clinical Significance
- Benign finding — does not require further workup when stable and in the expected post-treatment setting
- Listed under “Other Findings — Typically Benign” in BI-RADS v2025, meaning it should not elevate the BI-RADS assessment category
- The presence of post-therapy changes can obscure underlying recurrence — careful comparison with prior studies and attention to any new focal abnormality is essential
- Baseline post-treatment MRI (typically performed 12–18 months after radiation completion) establishes the expected appearance for future comparison
Pitfalls
- Mistaking post-therapy changes for inflammatory carcinoma — clinical history is essential; inflammatory carcinoma presents with rapid-onset skin thickening, erythema, and peau d’orange without prior treatment
- Ignoring new focal enhancement within diffuse post-therapy changes — recurrence can develop within a background of chronic post-radiation changes; any new focal mass or NME warrants further evaluation
- Bilateral post-therapy changes after unilateral treatment — if skin/trabecular thickening is bilateral, consider systemic causes (CHF, nephrotic syndrome, hypoalbuminemia) rather than attributing to radiation
- Assuming post-therapy changes are permanent — while some degree of skin thickening may persist indefinitely, progressive worsening after initial improvement is abnormal
Board Pearl
Always obtain a baseline post-treatment MRI approximately 12–18 months after completing radiation therapy. This establishes the “new normal” for comparison and prevents future false positives from stable post-therapy changes.
Reporting Guidance
- Describe: diffuse skin and trabecular thickening in the treated breast, consistent with post-therapy changes
- Compare: with baseline post-treatment study when available — note stability, improvement, or progression
- Flag: any new focal enhancement, mass, or non-mass enhancement within the treatment bed separately from the diffuse post-therapy changes
- Do not upgrade the BI-RADS category based solely on stable post-therapy skin/trabecular thickening
Related
- Other Findings Typically Benign
- Associated Feature — Skin Thickening
- Associated Feature — Skin Involvement
- Associated Feature — Skin Retraction
- Other Finding — Postoperative Collections
- Other Finding — Fat Necrosis
- Other Finding — Enhancing Skin Lesions
---
The enriched page grew from 25 lines to ~105 lines. Key additions:
- **Definition** section with precise terminology for trabecular and skin thickening
- **Imaging Appearance** across T2, T1, post-contrast, and DWI sequences
- **Temporal Evolution** table showing expected changes from 0–6 months through >3 years
- **DDx table** with 6 entities and distinguishing features (inflammatory carcinoma, infection, systemic edema, radiation recall, lymphatic obstruction)
- **Pitfalls** section covering 4 common mistakes
- **3 Board Pearls**: temporal progression red flags, skin thickening vs involvement distinction, baseline post-treatment MRI timing
- **Reporting Guidance** for structured dictation
- Expanded **Related** links from 2 to 7 wikilinks
Note: The provided source text (Kaur et al. rectal cancer staging) was unrelated to this breast MRI topic, so enrichment was based on the BI-RADS v2025 source text from `MRI_birads2025.pdf` page 134 and cross-referenced wiki pages.